Navigation Links
Cannabis use mimics cognitive weakness that can lead to schizophrenia
Date:11/2/2012

Researchers at the University of Bergen in Norway have found new support for their theory that cannabis use causes a temporary cognitive breakdown in non-psychotic individuals, leading to long-term psychosis. In an fMRI study published this week in Frontiers in Psychiatry, researchers found a different brain activity pattern in schizophrenia patients with previous cannabis use than in schizophrenic patients without prior cannabis use.

The results reinforce the researchers' model where cannabis users suffering from schizophrenia actually may have higher cognitive abilities than non-cannabis using schizophrenics. This difference may indicate that the cannabis-user group did not have the same mental propensity for psychosis.

"While brain activity for both groups was similar, there are subtle differences between schizophrenia sufferers with a history of cannabis use and those who have never used cannabis. These differences lead us to believe that the cognitive weakness leading to schizophrenia is imitated by the effects of cannabis in otherwise non-psychotic people," explains Else-Marie Loeberg, lead author on the article and associate professor of Psychology at the University of Bergen, Norway.

The 26 patients involved in the study attempted difficult cognitive tasks while in the fMRI machine. They were asked to listen to different syllables in each ear and try to say which syllable was spoken when instructed to concentrate on either the left or right eara difficult task for anyone but particularly difficult for schizophrenia patients who often have impaired attention, limited executive functioning and difficulty in processing verbal cues.

The study shows that schizophrenia sufferers with previous cannabis use had consistently higher levels of brain activity while undergoing these tests as well as a higher number of correct answers. These results are in line with previous conclusions from the Bergen researchers who support the idea that cannabis users with schizophrenic characteristics do not appear to suffer from the same neuro-cognitive weaknesses as other patients with schizophrenia.

This implies that it is the cannabis use itself that leads otherwise non-psychotic individuals down the nightmarish path towards schizophrenia by imitating the cognitive weakness that is the main risk factor for developing the psychological condition.


'/>"/>

Contact: Michael Mitchell
michael.mitchell@frontiersin.org
41-798-103-107
Frontiers
Source:Eurekalert

Related biology news :

1. U of S researchers discover cannabis pharma factory
2. To drive infections, a hijacking virus mimics a cells signaling system
3. Researchers develop ginseng-fortified milk to improve cognitive function
4. Piglets in mazes provide insights into human cognitive development
5. LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS
6. Brain training may lessen cognitive impairments associated with coronary bypass surgery
7. Evolving to fight epidemics: Weakness can be an advantage
8. Weakness can be an advantage in surviving deadly parasites, a new study shows
9. The music of the (hemi)spheres sheds new light on schizophrenia
10. Johns Hopkins researchers link 2 biological risk factors for schizophrenia
11. Researchers pursue red flag for schizophrenia relapse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: